Advertisement
Advertisement
KAPA
Kairos Pharma, Ltd.
0.59
USDSponsored
-0.04
-6.86%
Feb 05, 15:49 UTC -5
Closed
Pre-Market
0.60
+0.01
+1.36%
KAPA Earnings Reports
Positive Surprise Ratio
KAPA beat 0 of 5 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Kairos Pharma, Ltd. earnings per share and revenue
On Nov 14, 2025, KAPA reported earnings of -0.07 USD per share (EPS) for Q3 25, missing the estimate of -0.06 USD, resulting in a -2.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.85% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
What were Kairos Pharma, Ltd.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kairos Pharma, Ltd. reported EPS of -$0.07, missing estimates by -2.94%, and revenue of $0.00, 0% as expectations.
How did the market react to Kairos Pharma, Ltd.'s Q3 2025 earnings?
The stock price moved up 4.85%, changed from $0.79 before the earnings release to $0.83 the day after.
When is Kairos Pharma, Ltd. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Kairos Pharma, Ltd.'s next earnings report?
Based on --
analysts, Kairos Pharma, Ltd. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement